Literature DB >> 21499495

Renin and cardiovascular disease: Worn-out path, or new direction.

Gaurav Alreja1, Jacob Joseph.   

Abstract

Inhibition of the renin angiotensin system has beneficial effects in cardiovascular prevention and treatment. The advent of orally active direct renin inhibitors adds a novel approach to antagonism of the renin-angiotensin system. Inhibition of the first and rate-limiting step of the renin angiotensin cascade offers theoretical advantages over downstream blockade. However, the recent discovery of the (pro)renin receptor which binds both renin and prorenin, and which can not only augment catalytic activity of both renin and prorenin in converting angiotensinogen to angiotensin I, but also signal intracellularly via various pathways to modulate gene expression, adds a significant level of complexity to the field. In this review, we will examine the basic and clinical data on renin and its inhibition in the context of cardiovascular pathophysiology.

Entities:  

Keywords:  Angiotensin; Cardiovascular disease; Prorenin receptor; Renin; Renin receptor

Year:  2011        PMID: 21499495      PMCID: PMC3077814          DOI: 10.4330/wjc.v3.i3.72

Source DB:  PubMed          Journal:  World J Cardiol


  129 in total

Review 1.  Molecular mechanisms of human hypertension.

Authors:  R P Lifton; A G Gharavi; D S Geller
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 2.  Human prorenin.

Authors:  W A Hsueh; J D Baxter
Journal:  Hypertension       Date:  1991-04       Impact factor: 10.190

3.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

4.  Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in rats.

Authors:  Chun-Yen Ke; Chia-Chi Lee; Chung-Jen Lee; Yi-Maun Subeq; Ru-Ping Lee; Bang-Gee Hsu
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

5.  Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution.

Authors:  A R Sielecki; K Hayakawa; M Fujinaga; M E Murphy; M Fraser; A K Muir; C T Carilli; J A Lewicki; J D Baxter; M N James
Journal:  Science       Date:  1989-03-10       Impact factor: 47.728

6.  Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis.

Authors:  Matthew R Weir; Christopher Bush; David R Anderson; Jack Zhang; Deborah Keefe; Andrew Satlin
Journal:  J Am Soc Hypertens       Date:  2007 Jul-Aug

7.  A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein.

Authors:  Jan H Schefe; Mario Menk; Jana Reinemund; Karin Effertz; Robin M Hobbs; Pier Paolo Pandolfi; Patricia Ruiz; Thomas Unger; Heiko Funke-Kaiser
Journal:  Circ Res       Date:  2006-11-02       Impact factor: 17.367

8.  Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.

Authors:  S Vaidyanathan; J Valencia; C Kemp; C Zhao; C-M Yeh; M-N Bizot; J Denouel; H A Dieterich; W P Dole
Journal:  Int J Clin Pract       Date:  2006-11       Impact factor: 2.503

9.  Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.

Authors:  Byung-Hee Oh; Jerry Mitchell; James R Herron; Jenny Chung; Mahmudul Khan; Deborah L Keefe
Journal:  J Am Coll Cardiol       Date:  2007-03-20       Impact factor: 24.094

10.  Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.

Authors:  Y Huang; S Wongamorntham; J Kasting; D McQuillan; R T Owens; L Yu; N A Noble; W Border
Journal:  Kidney Int       Date:  2006-01       Impact factor: 18.998

View more
  3 in total

Review 1.  Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment.

Authors:  Yasushi Matsuzawa; Amir Lerman
Journal:  Coron Artery Dis       Date:  2014-12       Impact factor: 1.439

2.  Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials.

Authors:  Shuang Li; Yan Wu; Ge Yu; Qing Xia; Yawei Xu
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

3.  Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome.

Authors:  Jacob E Pruett; Edgar D Torres Fernandez; Steven J Everman; Ruth M Vinson; Kacey Davenport; Madelyn K Logan; Stephanie A Ye; Damian G Romero; Licy L Yanes Cardozo
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.